<DOC>
	<DOCNO>NCT03104322</DOCNO>
	<brief_summary>Pilot-scale , open-label , randomised , two-period crossover study idiopathic pulmonary fibrosis ( IPF ) 16 week . Patients use electronic health journal ( patientMpower platform ) record treatment compliance , force vital capacity ( FVC ; daily ) , impact IPF daily life ( weekly ) symptom . Objectives characterise acceptability patientMpower platform patient &amp; healthcare professional perspective , impact active engagement self-monitoring use patientMpower platform Patient Reported Outcome Measures ( PROMs ) IPF , impact patientMpower platform medication compliance correlation patient-reported PROMs &amp; FVC clinical outcome .</brief_summary>
	<brief_title>Patient-reported Monitoring Symptoms Spirometry Via patientMpower Platform Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>confirm diagnosis idiopathic pulmonary fibrosis ( IPF ) . daily unrestricted access smartphone tablet device home . demonstrate understanding protocol correct use Spirobank Smart spirometer patientMpower platform . able willing perform spirometry every day home . willing give write informed consent significant confusion concomitant medical condition would limit ability patient record symptom use home spirometer regular basis . new prescription antifibrotic therapy IPF ( e.g . pirfenidone , nintedanib ) within 4 week baseline visit . recent exacerbation IPF clinically significant change patient 's medical condition 4 week baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>digital health</keyword>
	<keyword>home spirometry</keyword>
	<keyword>patient report outcome measure</keyword>
	<keyword>e-health</keyword>
	<keyword>pirfenidone</keyword>
	<keyword>nintedanib</keyword>
	<keyword>FVC</keyword>
	<keyword>antifibrotic</keyword>
</DOC>